Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Obizur

- PMLiVE

Express Scripts ‘will pay $750m on PCSK9 inhibitors next year’

Amgen's Repatha and Sanofi's Praluent included

- PMLiVE

Keryx Biopharmaceuticals’ Fexeric approved in EU

New treatment option for chronic kidney disease

- PMLiVE

Grunenthal and AcelRx’s Zalviso approved in EU

Provides new treatment for post-operative pain

Shire Basingstoke

Shire wins EU approval for prolonged-release ADHD drug

First treatment in its class to be licensed for ADHD in Europe

- PMLiVE

PCSK9 inhibitors vastly over-priced, says ICER report

Cost of new Amgen and Sanofi drugs comes under fire

EU flag

Shire and Baxalta drugs among CHMP’s latest recommendations

New drugs for ADHD and haemophilia backed forEuropean approval

- PMLiVE

Sanofi’s cholesterol drug Praluent backed for European approval

CHMPdecision puts firm on-course to catch up with Amgen's Repatha

- PMLiVE

Amgen beats Sanofi to PCSK9 inhibitor market

EC approval for Repatha gives it a lead over Praluent

- PMLiVE

Praluent and Repatha backed for approval in US

Sanofi and Amgen remain in fierce competition in PCSK9 inhibitors

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

FDA panel backs new antifungal Cresemba

Basilea/Astellas drug tipped to become a $500m product

- PMLiVE

FDA backs Cubist’s antibiotic Zerbaxa

Combination cephalosporin and beta lactamase inhibitor wins US approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links